TREATMENT OF PRURITUS WITH P2X3 MODULATORS
Methods of treating pruritus in a mammal with a P2X3 antagonist are disclosed. Said P2X3 antagonist is preferably a compound of Formula (I). Said pruritus may be associated with an inflammatory skin disorder, an infectious skin disease, an autoimmune skin disease or a pregnancy-related skin disease. The P2X3 antagonist may be administered by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, topical administration or ophthalmic administration and may be used in conjunction with a NK-1 antagonist. The P2X3 antagonist acts by inhibiting pathological ATP release associated with hyperexcitability of afferent pruriceptive neurons, thus dampening peripheral hypersensitivity to itch via broad mechanism independent on the pathological stimuli acting at itch receptors.
1 . A method of treating pruritus in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a P2X3 antagonist.
2 . The method of claim 1 , wherein the P2X3 antagonist is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Formula (I) is:
R 1 is selected from the group consisting of cyano, halogen, methyl, and ethyl;
R 2 is selected from the group consisting of hydrogen, halogen, methyl, and ethyl;
R 3 is selected from the group consisting of halogen, methyl, and ethyl;
R 4 is selected from the group consisting of hydrogen, halogen, methyl, ethyl, and methoxy;
R 5 and R 6 are independently selected from the group consisting of hydrogen, C 1 -C 6 -alkyl, and hydroxy-C 1 -C 6 -alkyl; or
R 5 and R 6 , together with the nitrogen to which they are both attached, form a 5- or 6-member heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, and C 1 -C 4 -alkyl;
R 7 and R 8 are independently selected from the group consisting of hydrogen and C 1 -C 4 -alkyl;
R 9 is selected from the group consisting of C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, C 1 -C 6 -alkyl-C 3 -C 6 -cycloalkyl, halo-C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, halo-C 1 -C 6 -alkoxy, and C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl; and
X is selected from the group consisting of a bond, CH 2 , and O.
3 . The method of claim 2 , wherein R 1 is methyl and R 2 is hydrogen.
4 . The method of claim 2 , wherein R 3 and R 4 are fluoro.
5 . The method of claim 2 , wherein X is O.
6 . The method of claim 2 , wherein the compound corresponds in structure to:
R 4 is selected from the group consisting of halogen, methyl, and ethyl.
7 . The method of claim 2 , wherein R 5 is hydrogen and R 6 is C 1 -C 6 -alkyl.
8 . The method of claim 2 , wherein R 6 is methyl.
9 . The method of claim 2 , wherein R 7 and R 8 are hydrogen.
10 . The method of claim 2 , wherein R 9 is C 1 -C 6 -alkoxy.
11 . The method of claim 2 , wherein R 9 is methoxy.
12 . The method of claim 2 , wherein the compound corresponds in structure to:
13 . The method of claim 2 , wherein the compound corresponds in structure to:
14 . The method of claim 2 , wherein the compound corresponds in structure to:
15 . The method of claim 2 , wherein the compound corresponds in structure to:
16 . The method of claim 2 , wherein the compound corresponds in structure to:
17 . The method of claim 2 , wherein the compound corresponds in structure to:
18 . The method of claim 1 , wherein the P2X3 antagonist corresponds in structure to:
19 . The method of claim 1 , wherein the P2X3 antagonist corresponds in structure to:
20 . The method of claim 1 , wherein the P2X3 antagonist corresponds in structure to:
21 . The method of any one of claims 1 - 20 , wherein the mammal is a human.
22 . The method of any one of claims 1 - 21 , wherein the pruritus is associated with an inflammatory skin disease, an infectious skin disease, an autoimmune skin disease, or a pregnancy-related skin disease.
23 . The method of claim 22 , wherein the pruritus is associated with an inflammatory skin disease selected from the group consisting of atopic dermatitis, allergic, irritant contact dermatitis, exsiccation dermatitis, nummular and dyshidrotic dermatitis, lichen planus, lichen sclerosus et atrophicus, polymorphous light eruption psoriasis, Grover's disease, mucinosis, mastocytosis, and urticaria.
24 . The method of claim 22 , wherein the pruritus is associated with an infectious skin disease selected from the group consisting of mycoses, bacterial and viral infections, scabies, pediculosis, insect bites, and folliculitides.
25 . The method of claim 22 , wherein the pruritus is associated with an autoimmune skin disease selected from the group consisting of dermatitis herpetiformis (Duhring's disease), bullous pemphigoid; genodermatoses, Darier's disease, and Hailey-Hailey disease.
26 . The method of claim 22 , wherein the pruritus is associated with a pregnancy-related skin disease selected from the group consisting of polymorphic eruption of pregnancy (PEP), atopic eruption of pregnancy, pemphigoid gestationis, neoplasias, and cutaneous T-cell lymphoma.
27 . The method of any one of claims 1 - 21 , wherein the pruritus is associated with prurigo nodularis.
28 . The method of any one of claims 1 - 21 , wherein the pruritus is associated with a kidney disease or a therapeutic procedure to treat a kidney disease.
29 . The method of claim 28 , wherein the pruritus is associated with a chronic kidney disease.
30 . The method of claim 28 , wherein the pruritus is associated with a therapeutic procedure to treat a kidney disease, wherein the therapeutic procedure to treat the kidney disease is selected from the group consisting of hemodialysis and peritoneal dialysis.
31 . The method of any one of claims 1 - 21 , wherein the pruritus is associated with a medical procedure or treatment.
32 . The method of claim 31 , wherein the pruritus is associated with a medical treatment with a drug selected from the group consisting of opioids, anti-malarial drugs, anti-cancer therapies and epidermal growth factor receptor inhibitors.
33 . The method of any one of claims 1 - 32 , wherein the P2X3 antagonist is formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, topical administration, or ophthalmic administration.
34 . The method of claim 33 , wherein the pharmaceutical composition is in the form of a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion.
35 . The method of any one of claims 1 - 34 , further comprising the administration of a second therapeutic agent.
36 . The method of any one of claims 1 - 35 , further comprising the administration of a NK-1 antagonist.
37 . The method of claim 36 , wherein the NK-1 antagonist is selected from the group consisting of serlopitant, aprepitant, casopitant, dapitant, ezlopitant, fosaprepitant, lanepitant, maropitant, netupitant, nolpitant, orvepitant, rolapitant, vestipitant, vofopitant, AV-818, BIIF 1149CL, CP122,721, DNK-333, GSK-424887, L-733060, L-759274, LY-686017, M516102, and TA-5538.